Results 151 to 160 of about 70,065 (194)

Survival improvement with sirolimus plus tacrolimus immunosuppression for treatment of bronchiolitis obliterans syndrome after lung transplantation. [PDF]

JHLT Open
Wijesinha M, Terrin M, Pham S, Iacono A.
europepmc   +1 more source

A plain language summary of the AMPECT study: nab-sirolimus for advanced malignant perivascular epithelioid cell tumors. [PDF]

Future Oncol
Wagner AJ, Ravi V, Riedel RF, Ganjoo K, Van Tine BA, Chugh R, Cranmer L, Gordon EM, Hornick JL, Du H, Polson KM, Yalamanchili S, DeBoer C, Ding L, Schmid AN, Navarro WH, Kwiatkowski DJ, Dickson MA.   +17 more
europepmc   +1 more source

State-of-the-Art Definitive Femoropopliteal Lesion Treatment: A Case-Based Systematic Approach. [PDF]

J Cardiovasc Dev Dis
Korosoglou G, Malyar N, Schmidt A, Lichtenberg M, Grözinger G, Böckler D, Behrendt CA, Blessing E, Langhoff R, Zeller T, Rammos C.   +10 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Molecular actions of sirolimus: sirolimus and mTor

Transplantation Proceedings, 2003
Recent therapeutic strategies to combat organ allograft rejection have focused on T-cell signaling pathways and the molecules that comprise them. The macrolide antibiotic produced by the bacterium Streptomyces hygroscopicus, known as sirolimus or rapamycin, has shown great therapeutic potential in the transplant setting.
R A, Kirken, Y L, Wang
openaire   +2 more sources

Sirolimus

Reactions Weekly, 2007
  +5 more sources

Sirolimus and growth

Pediatric Transplantation, 2011
Fernando, Santos, Oscar, Alvarez-García, David, González   +2 more
openaire   +2 more sources

Sirolimus

Reactions Weekly, 2012
  +4 more sources

Sirolimus

Reactions Weekly, 2006
  +5 more sources

Sirolimus

Reactions Weekly, 2017
  +6 more sources

Sirolimus

Reactions Weekly, 2008
openaire   +2 more sources